Mangoceuticals, Inc.
MGRX Healthcare Health Information Services
Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024. In the quarter to June 2026, revenue fell 59.1%, EPS grew 84.2% and free cash flow grew 79.3%, each against the same quarter a year earlier.
Follow MGRX
Mangoceuticals, Inc. (MGRX) EV/Sales
As of 16 October 2026, Mangoceuticals, Inc. (MGRX) trades at a EV/Sales of 15.6×. Over the past ten years it has ranged from 0.0× (September 2023) to 66.6× (October 2025); the current reading is higher than 66% of that period. That is above the Health Information Services industry median of 2.6× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.1× | 70.36% |
| FY2024 | 7.7× | 42.82% |
| FY2023 | 5.4× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 19.9× | 43.32% |
| Mar 2026 | 13.9× | 6.15% |
| Dec 2025 | 13.1× | (75.33%) |
| Sep 2025 | 53.0× | 81.55% |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ACON Aclarion, Inc. compare | −137× |
| HLTHQ Cue Health Inc. compare | −1.1× |
| ZCMD Zhongchao Inc. compare | −0.4× |
| ETAOF ETAO International Co., Ltd. compare | n/m |
| VSEED VSee Health, Inc. compare | 0.2× |
| HCTI Healthcare Triangle, Inc. compare | 0.4× |
| RNLXY Renalytix plc - Sponsored ADR compare | 2.5× |
| BFRG Bullfrog AI Holdings Inc. compare | 7.0× |
| MGRX Mangoceuticals, Inc. | 15.6× |
| Health Information Services industry median | 2.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)